About Fulcrum Therapeutics
Fulcrum Therapeutics is a company based in Cambridge (United States) founded in 2015.. Fulcrum Therapeutics has raised $114.67 million across 4 funding rounds from investors including Fidelity Investments, Perceptive Advisors and SVB Securities. The company has 45 employees as of December 31, 2024. Fulcrum Therapeutics offers products and services including Pociredir and Gene Modulation Programs. Fulcrum Therapeutics operates in a competitive market with competitors including Moderna, Insitro, BridgeBio, Alnylam and ATAI, among others.
- Headquarter Cambridge, United States
- Employees 45 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Fulcrum Therapeutics, Inc.
-
Annual Revenue
$80 M2752.05as on Dec 31, 2024
-
Net Profit
$-9.72 M90.01as on Dec 31, 2024
-
EBITDA
$-18.24 M83.19as on Dec 31, 2024
-
Total Equity Funding
$114.67 M (USD)
in 4 rounds
-
Latest Funding Round
$68.5 M (USD), Post-IPO
Jun 10, 2020
-
Investors
Fidelity Investments
& 16 more
-
Employee Count
45
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Fulcrum Therapeutics
Fulcrum Therapeutics is a publicly listed company on the NASDAQ with ticker symbol FULC in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Fulcrum Therapeutics
Fulcrum Therapeutics offers a comprehensive portfolio of products and services, including Pociredir and Gene Modulation Programs. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Investigational treatment for sickle cell disease via gene modulation
Develops therapies targeting beta-thalassemia and other genetic conditions
Unlock access to complete
Unlock access to complete
Leadership Team
11 people
Board Team
7 people
Software Development Team
7 people
Senior Team
6 people
Product Management Team
4 people
Finance and Accounting
2 people
Operations Team
2 people
Human Resources and Administration
1 people
Unlock access to complete
Funding Insights of Fulcrum Therapeutics
Fulcrum Therapeutics has successfully raised a total of $114.67M across 4 strategic funding rounds. The most recent funding activity was a Post-IPO round of $68.5 million completed in June 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Post-IPO — $68.5M
-
First Round
First Round
(10 May 2017)
- Investors Count 17
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun, 2020 | Amount | Post-IPO - Fulcrum Therapeutics | Valuation |
investors |
|
| Sep, 2018 | Amount | Series B - Fulcrum Therapeutics | Valuation | Foresite Capital | |
| Jul, 2017 | Amount | Series A - Fulcrum Therapeutics | Valuation | Third Rock Ventures |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Fulcrum Therapeutics
Fulcrum Therapeutics has secured backing from 17 investors, including institutional and venture fund investors. Prominent investors backing the company include Fidelity Investments, Perceptive Advisors and SVB Securities. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Biotech startups are funded by this venture capital firm.
|
Founded Year | Domain | Location | |
|
Investing in Life Sciences sectors like Healthcare and Biotechnology.
|
Founded Year | Domain | Location | |
|
Multi-stage investment firm invests in healthcare and life sciences companies
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Fulcrum Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Fulcrum Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Fulcrum Therapeutics Comparisons
Competitors of Fulcrum Therapeutics
Fulcrum Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Insitro, BridgeBio, Alnylam and ATAI, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| domain | founded_year | HQ Location |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| domain | founded_year | HQ Location |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| domain | founded_year | HQ Location |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases are developed to treat patients.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Fulcrum Therapeutics
Frequently Asked Questions about Fulcrum Therapeutics
When was Fulcrum Therapeutics founded?
Fulcrum Therapeutics was founded in 2015 and raised its 1st funding round 2 years after it was founded.
Where is Fulcrum Therapeutics located?
Fulcrum Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Who is the current CEO of Fulcrum Therapeutics?
Robert Gould is the current CEO of Fulcrum Therapeutics.
Is Fulcrum Therapeutics a funded company?
Fulcrum Therapeutics is a funded company, having raised a total of $114.67M across 4 funding rounds to date. The company's 1st funding round was a Series A of $29.67M, raised on May 10, 2017.
How many employees does Fulcrum Therapeutics have?
As of Dec 31, 2024, the latest employee count at Fulcrum Therapeutics is 45.
What is the annual revenue of Fulcrum Therapeutics?
Annual revenue of Fulcrum Therapeutics is $80M as on Dec 31, 2024.
What does Fulcrum Therapeutics do?
Fulcrum Therapeutics is focused on discovering and developing small molecules that modulate the onoff control mechanisms that regulate genes. The Fulcrum product engine integrates insights from four scientific disciplines (Gene Regulation, Human Genetics and Disease, Cell Biology, and Screening and Computation) to identify novel drug targets and develop breakthrough medicines. The early focus of Fulcrums product engine is on two severe genetic diseases: Fragile X syndrome (FXS) and a form of muscular dystrophy called facioscapulohumeral muscular dystrophy (FSHD). Each disease arises from a single gene mutation that creates an error in gene regulation. In the case of Fragile X, the silencing of the FMR1 gene eliminates the cells ability to make a protein needed for brain function. In FSHD, the precipitating event is the activation of a gene called DUX4 that should be silent in adulthood. This activation leads to muscle wasting as cells die.
Who are the top competitors of Fulcrum Therapeutics?
Fulcrum Therapeutics's top competitors include Moderna, Spark Therapeutics and BridgeBio.
What products or services does Fulcrum Therapeutics offer?
Fulcrum Therapeutics offers Pociredir and Gene Modulation Programs.
Is Fulcrum Therapeutics publicly traded?
Yes, Fulcrum Therapeutics is publicly traded on NASDAQ under the ticker symbol FULC.
Who are Fulcrum Therapeutics's investors?
Fulcrum Therapeutics has 17 investors. Key investors include Fidelity Investments, Perceptive Advisors, SVB Securities, Monashee Investment Management, and EcoR1.
What is Fulcrum Therapeutics's ticker symbol?
The ticker symbol of Fulcrum Therapeutics is FULC on NASDAQ.